Procter & Gamble Health Intrinsic Value
Procter & Gamble Health (PGHL) median intrinsic value is ₹2093.23 from 9 valuation models (range ₹1250–₹3124), vs current price ₹6247.50 — -66.5% downside (Trading Above Calculated Value), margin of safety -100.0%. Also explore PGHL share price history to track price trends across different timeframes.
PGHL Valuation Methods Summary — DCF, Graham Number & P/E
Procter & Gamble Health intrinsic value across 9 models vs current price ₹6247.50 — upside/downside and value range per method. For current market price and key ratios, visit Procter & Gamble Health stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹3102.00 | ₹2481.60 - ₹3722.40 | -50.3% | EPS: ₹141.00, Sector P/E: 22x |
| Book Value Method | asset | ₹1249.50 | ₹1124.55 - ₹1374.45 | -80.0% | Book Value/Share: ₹308.82, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1874.25 | ₹1686.83 - ₹2061.68 | -70.0% | Revenue/Share: ₹555.88, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2499.00 | ₹2249.10 - ₹2748.90 | -60.0% | EBITDA: ₹329.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2499.00 | ₹1999.20 - ₹2998.80 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹1874.25 | ₹1686.83 - ₹2061.68 | -70.0% | EPS Growth: 7.1%, Fair P/E: 5.7x |
| Growth Adjusted P/E | growth | ₹2093.23 | ₹1883.91 - ₹2302.55 | -66.5% | Revenue Growth: -2.1%, Adj P/E: 14.8x |
| ROE Based Valuation | profitability | ₹3123.75 | ₹2811.38 - ₹3436.13 | -50.0% | ROE: 44.6%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1874.25 | ₹1686.83 - ₹2061.68 | -70.0% | EPS: ₹141.00, BVPS: ₹308.82 |
PGHL Intrinsic Value vs Market Price — All Valuation Models
Procter & Gamble Health fair value range ₹1250–₹3124 vs current market price ₹6247.50 across 9 valuation models. Browse Procter & Gamble Health annual reports for revenue, profit, balance sheet and cash flow data.
PGHL Intrinsic Value Analysis — Undervalued or Overvalued?
Procter & Gamble Health median intrinsic value ₹2093.23, current price ₹6247.50 — Trading Above Calculated Value by 66.5%, margin of safety -100.0%.
What is the intrinsic value of PGHL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Procter & Gamble Health (PGHL) is ₹2093.23 (median value). With the current market price of ₹6247.50, this represents a -66.5% variance from our estimated fair value.
The valuation range spans from ₹1249.50 to ₹3123.75, indicating ₹1249.50 - ₹3123.75.
Is PGHL undervalued or overvalued?
Based on our multi-method analysis, Procter & Gamble Health (PGHL) appears to be trading above calculated value by approximately 66.5%.
PGHL Financial Health — Key Ratios vs Industry Benchmarks
Procter & Gamble Health financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.97 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 44.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 34.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.12x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
PGHL Cash Flow Quality — Operating & Free Cash Flow
Procter & Gamble Health operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹169 Cr | ₹169 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹228 Cr | ₹225 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹236 Cr | ₹225 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹170 Cr | ₹157 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹247 Cr | ₹231 Cr | Positive Free Cash Flow | 8/10 |